Epidermal Growth Factor Receptor Mutation-Positive
Non-Small-Cell Lung Cancer in the Real-World Setting in Central
Europe The INSIGHT Study

J 2015

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study

RAMLAU, Rodryg, Tanja CUFER, Peter BERZINEC, Rafal DZIADZIUSZKO, Wlodzimier OSLZEWSKI et. al.

Základní údaje

Originální název

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study

Autoři

RAMLAU, Rodryg (616 Polsko), Tanja CUFER (705 Slovinsko), Peter BERZINEC (703 Slovensko), Rafal DZIADZIUSZKO (616 Polsko), Wlodzimier OSLZEWSKI (616 Polsko), Helmut POPPER (40 Rakousko), Paolo BAJCIC (40 Rakousko), Ladislav DUŠEK (203 Česká republika, domácí), Zuzana ZBOŽÍNKOVÁ (203 Česká republika, garant, domácí) a Robert PIRKER (40 Rakousko)

Vydání

Journal of Thoracic Oncology, Philadelphia, Lippincott Williams & Wilkins, 2015, 1556-0864

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.040

Kód RIV

RIV/00216224:14110/15:00083972

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1097/JTO.0000000000000621

UT WoS

000360365400018

Klíčová slova anglicky

Targeted therapy; INSIGHT; EGFR mutations; Molecular analysis

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 9. 2015 15:37, Soňa Böhmová

Anotace

V originále

The ImplementatioN of perSonalized medicine In NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.

Citovat

RAMLAU, Rodryg, Tanja CUFER, Peter BERZINEC, Rafal DZIADZIUSZKO, Wlodzimier OSLZEWSKI, Helmut POPPER, Paolo BAJCIC, Ladislav DUŠEK, Zuzana ZBOŽÍNKOVÁ a Robert PIRKER. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study. Journal of Thoracic Oncology. Philadelphia: Lippincott Williams & Wilkins, 2015, roč. 10, č. 9, s. 1370-1374. ISSN 1556-0864. Dostupné z: https://dx.doi.org/10.1097/JTO.0000000000000621.

@article{1312075,
   author = {Ramlau, Rodryg and Cufer, Tanja and Berzinec, Peter and Dziadziuszko, Rafal and Oslzewski, Wlodzimier and Popper, Helmut and Bajcic, Paolo and Dušek, Ladislav and Zbožínková, Zuzana and Pirker, Robert},
   article_location = {Philadelphia},
   article_number = {9},
   doi = {http://dx.doi.org/10.1097/JTO.0000000000000621},
   keywords = {Targeted therapy; INSIGHT; EGFR mutations; Molecular analysis},
   language = {eng},
   issn = {1556-0864},
   journal = {Journal of Thoracic Oncology},
   title = {Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study},
   volume = {10},
   year = {2015}
}

TY  - JOUR
ID  - 1312075
AU  - Ramlau, Rodryg - Cufer, Tanja - Berzinec, Peter - Dziadziuszko, Rafal - Oslzewski, Wlodzimier - Popper, Helmut - Bajcic, Paolo - Dušek, Ladislav - Zbožínková, Zuzana - Pirker, Robert
PY  - 2015
TI  - Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study
JF  - Journal of Thoracic Oncology
VL  - 10
IS  - 9
SP  - 1370-1374
EP  - 1370-1374
PB  - Lippincott Williams & Wilkins
SN  - 15560864
KW  - Targeted therapy
KW  - INSIGHT
KW  - EGFR mutations
KW  - Molecular analysis
N2  - The ImplementatioN of perSonalized medicine In NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.
ER  -

RAMLAU, Rodryg, Tanja CUFER, Peter BERZINEC, Rafal DZIADZIUSZKO, Wlodzimier OSLZEWSKI, Helmut POPPER, Paolo BAJCIC, Ladislav DUŠEK, Zuzana ZBOŽÍNKOVÁ a Robert PIRKER. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study. \textit{Journal of Thoracic Oncology}. Philadelphia: Lippincott Williams \&{} Wilkins, 2015, roč.~10, č.~9, s.~1370-1374. ISSN~1556-0864. Dostupné z: https://dx.doi.org/10.1097/JTO.0000000000000621.

Přehled o publikaci